United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1129,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "727adca4-03df-461f-b2b6-d794c21bc248",
"title": "Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"description": "Summary Regeneron Pharmaceuticals Inc (REGN) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® (cemiplimab)",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Summary\n\nRegeneron Pharmaceuticals Inc (REGN, Financial) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® ...",
"url": "https://www.gurufocus.com/news/2899945/regeneron-pharmaceuticals-inc-regn-announces-promising-phase-3-trial-results-for-libtayo-in-highrisk-cscc-regn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 103.061874,
"sentiment_score": 0.37095,
"highlights": [
{
"highlight": "Summary\n\n<em>Regeneron</em> <em>Pharmace[+241 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em> (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "823164da-ec1c-48cf-be21-2962d5bdd948",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing",
"description": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and",
"keywords": "GuruFocus, Article, News, Marketwired, REGN",
"snippet": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)\n\nLibtayo also demonstrated 80% and...",
"url": "https://www.gurufocus.com/news/2899929/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 19.57739,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.576618,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.575602,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "7a204204-ec07-467a-84b4-9dde533d59d9",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing | REGN Stock News",
"description": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery. Trial reveals 87% disease",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery.\n\nTrial reveals 87% disease-free s...",
"url": "https://www.gurufocus.com/news/2899915/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:27.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.920944,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.919144,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 40.91459,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.910954,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "397c2098-b811-44a8-9ba7-2a6966e5b96e",
"title": "Gilead Sciences Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"description": "Summary Gilead Sciences Inc (GILD) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab), significa",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Summary\n\nGilead Sciences Inc (GILD, Financial) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab...",
"url": "https://www.gurufocus.com/news/2899943/gilead-sciences-inc-gild-announces-promising-results-for-trodelvy-and-keytruda-combination-in-breast-cancer-treatment-gild-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.39114,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+342 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> <em>Inc</em> (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "876385dc-a25d-43b0-8b64-188ef12d8a28",
"title": "Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer",
"description": "Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progre",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:GILD",
"snippet": "Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progres...",
"url": "https://www.gurufocus.com/news/2899927/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-firstline-pdl1-metastatic-triplenegative-breast-cancer",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.270554,
"sentiment_score": -0.16755,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+357 characters]",
"sentiment": -0.802,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Gilead</em> <em>Sciences</em>\n[+225 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Trodelvy, Gilead and the Gilead logo are[+191 characters]",
"sentiment": -0.4824,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about Gilead, pleas[+265 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.88321,
"sentiment_score": -0.4438,
"highlights": [
{
"highlight": "KEYTRUDA® is a registered trademark of [+322 characters]",
"sentiment": -0.8876,
"highlighted_in": "main_text"
},
{
"highlight": "About the ASCENT-04/KEYNOTE-D19 Study\n\nI[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "2019a865-9d25-4977-ac19-ace4217cad96",
"title": "Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer | GILD Stock News",
"description": "Gilead Sciences (GILD) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC). The combination of Trode",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC).\n\nThe combination of T...",
"url": "https://www.gurufocus.com/news/2899921/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-firstline-pdl1-metastatic-triplenegative-breast-cancer-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-05-31T13:16:09.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.566433,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.56643,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.566147,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "611a224c-4099-4900-baa5-b0c907a34d74",
"title": "Tempus AI Inc (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"description": "Summary Tempus AI Inc (TEM), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive proprietary",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "Summary\n\nTempus AI Inc (TEM, Financial), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive...",
"url": "https://www.gurufocus.com/news/2899941/tempus-ai-inc-tem-launches-fuses-program-to-revolutionize-precision-medicine-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:47.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 108.49646,
"sentiment_score": 0.39598,
"highlights": [
{
"highlight": "Summary\n\n<em>Tempus</em> <em>AI</em> <em[+205 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+176 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nAs [+308 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "The Fuses program is an initiative by <e[+322 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Tempus</em> <em>AI</em> <em>Inc</em> (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "0179765b-45fc-46b0-9be3-ede1c187d90f",
"title": "Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model",
"description": "Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of it",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:TEM",
"snippet": "Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its...",
"url": "https://www.gurufocus.com/news/2899935/tempus-introduces-fuses-a-program-designed-to-transform-therapeutic-research-and-build-the-largest-diagnostic-platform-using-its-novel-foundation-model",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 32.17685,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em>, <em>Inc</em[+180 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "1b99f129-7dd5-4755-af00-bc8b660384ba",
"title": "Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model | TEM Stock News",
"description": "Tempus AI, Inc. (TEM) launches Fuses program, leveraging its vast dataset for advanced diagnostic insights. The Fuses initiative aims to enhance precisi",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "Tempus AI, Inc. (TEM, Financial) launches Fuses program, leveraging its vast dataset for advanced diagnostic insights.\n\nThe Fuses initiative aims to enhance pre...",
"url": "https://www.gurufocus.com/news/2899924/tempus-introduces-fuses-a-program-designed-to-transform-therapeutic-research-and-build-the-largest-diagnostic-platform-using-its-novel-foundation-model-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:45:21.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 46.76872,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em>, <em>Inc</em[+339 characters]",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "9acf09b4-8101-4391-a58e-1b0799da52bf",
"title": "Notable analyst calls this week: Southwest Airlines, Regeneron and Nvidia among top picks",
"description": "Wall Street updates: Discover analysts' top stock upgrades, downgrades, and key market insights, featuring Nvidia, Southwest Airlines, Salesforce, and more.",
"keywords": "",
"snippet": "The S&P500 (SP500)closed in the red, after the week witnessed muted inflation data, a court striking down President Trump's April tariffs and earnings reports f...",
"url": "https://seekingalpha.com/news/4453945-notable-analyst-calls-this-week-southwest-airlines-regeneron-and-nvidia-among-top-picks",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185337728/image_2185337728.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T13:35:13.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 42.218803,
"sentiment_score": 0.10115,
"highlights": [
{
"highlight": "The S&P500 (SP500)closed in the red, aft[+252 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Notable analyst calls this week: Southwest Airlines, Regeneron and <em>Nvidia</em> among top picks",
"sentiment": 0.2023,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2a158005-d4bb-46f2-a50a-72e3bb7c4dbc",
"title": "エポスカードの外貨事務手数料が3.85％に改悪！代わりのお得なクレジットカード等を解説",
"description": "エポスカードは2025年7月1日(火)から、外貨事務手数料を改悪します。 Visa決済センターにて2025年7 ...",
"keywords": "",
"snippet": "エポスカードは2025年7月1日(火)から、外貨事務手数料を改悪します。\n\nVisa決済センターにて2025年7月1日から処理された?...",
"url": "https://matsunosuke.jp/post-215441/",
"image_url": "https://i0.wp.com/matsunosuke.jp/wp-content/uploads/2021/03/d861355b4446dc7e7833b0e7d8054ed8.png?fit=546%2C276&ssl=1",
"language": "ja",
"published_at": "2025-05-31T13:23:46.000000Z",
"source": "matsunosuke.jp",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.547972,
"sentiment_score": null,
"highlights": [
{
"highlight": "ANAマイレージクラブ / <em>Sony</[+788 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "公式サイトANAマイレージクラ?[+715 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "外貨建て決済のポイント還元?[+835 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "外貨建て決済のポイント還元?[+724 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "海外旅行でおすすめのクレジ?[+735 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "その他、ソニー銀行のデビッ?[+805 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "公式サイトANAマイレージクラ?[+613 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "388ef67e-212e-45fe-8106-40cf52c4c04b",
"title": "Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News",
"description": "Immatics' IMA203 PRAME cell therapy shows a 56% confirmed objective response rate in metastatic melanoma patients. The therapy demonstrates strong durab",
"keywords": "GuruFocus, Article, News, GuruFocus News, IMTX",
"snippet": "Immatics' IMA203 PRAME cell therapy shows a 56% confirmed objective response rate in metastatic melanoma patients.\n\nThe therapy demonstrates strong durability w...",
"url": "https://www.gurufocus.com/news/2899922/immatics-ima203-prame-cell-therapy-data-presented-at-2025-asco-annual-meeting-continues-to-show-strong-antitumor-activity-and-durability-in-patients-with-metastatic-melanoma-imtx-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BVAE.png?20",
"language": "en",
"published_at": "2025-05-31T13:16:14.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 48.957344,
"sentiment_score": 0.3071,
"highlights": [
{
"highlight": "<em>Immatics</em>' IMA203 PRAME cell the[+321 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> <em>N.V</em>. (IMTX, F[+210 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Encouraged by these results and the high[+281 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "The SUPRAME trial's primary endpoint is [+273 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "1ce66c47-defa-42e5-be95-5e8dcb2307e2",
"title": "Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma",
"description": "**media[642064]**",
"keywords": "Immatics, IMA203, PRAME, Cell, Therapy, Data, Presented, at, 2025, ASCO, Annual, Meeting, Continues, to, Show, Strong, Anti-tumor, Activity, and, Durability, in, Patients, with, Metastatic, Melanoma",
"snippet": "Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability an...",
"url": "https://www.manilatimes.net/2025/05/31/tmt-newswire/globenewswire/immatics-ima203-prame-cell-therapy-data-presented-at-2025-asco-annual-meeting-continues-to-show-strong-anti-tumor-activity-and-durability-in-patients-with-metastatic-melanoma/2124533",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/05/31/642064.png",
"language": "en",
"published_at": "2025-05-31T12:09:34.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.362354,
"sentiment_score": 0.147191,
"highlights": [
{
"highlight": "' global leadership in precision targeti[+123 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>IMTX</em>, \"<em>Im[+348 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "These individuals are in urgent need of [+136 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Trial-in-Progress Poster Summary - IMA20[+231 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> aims to submit a Biolo[+294 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Immatics</em> PRAME franchise cu[+282 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Immatics</em>\n\n<em>Immatics</e[+206 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> intends to use its web[+265 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "These forward-looking statements are bas[+255 characters]",
"sentiment": -0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please contact:\n\nM[+85 characters]",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
},
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 7.529414,
"sentiment_score": -0.0286,
"highlights": [
{
"highlight": "We view our progress in melanoma as a cr[+293 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Immatics is the global leader in precisi[+115 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Immatics PRAME <em>franchise</em> cu[+282 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "8f176243-d84c-4702-8520-4a55ecf7e708",
"title": "Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer | ARVN Stock News",
"description": "Vepdegestrant shows a significant 2.9-month improvement in median progression-free survival in ESR1-mutant breast cancer patients. Arvinas (ARVN) and Pf",
"keywords": "GuruFocus, Article, News, GuruFocus News, ARVN",
"snippet": "Vepdegestrant shows a significant 2.9-month improvement in median progression-free survival in ESR1-mutant breast cancer patients.\n\nArvinas (ARVN, Financial) an...",
"url": "https://www.gurufocus.com/news/2899916/arvinas-and-pfizers-vepdegestrant-significantly-improves-progressionfree-survival-for-patients-with-esr1mutant-erher2-advanced-breast-cancer-arvn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIBF.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:39.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.04847,
"sentiment_score": -0.21315,
"highlights": [
{
"highlight": "<em>Arvinas</em> (ARVN, Financial) and P[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer | ARVN Stock News",
"sentiment": -0.1531,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.52349,
"sentiment_score": -0.2732,
"highlights": [
{
"highlight": "Arvinas (ARVN, Financial) and <em>Pfizer[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 22.52349,
"sentiment_score": -0.2732,
"highlights": [
{
"highlight": "Arvinas (ARVN, Financial) and <em>Pfizer[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "e7ca6554-66d9-4e57-aea0-9f4f08113275",
"title": "In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti",
"description": "Guardant Health (GH) reveals findings from the largest study on molecular residual disease (MRD) in colon cancer. The Guardant Revealâ„¢ test can predic",
"keywords": "GuruFocus, Article, News, GuruFocus News, GH",
"snippet": "Guardant Health (GH, Financial) reveals findings from the largest study on molecular residual disease (MRD) in colon cancer.\n\nThe Guardant Reveal™ test can pr...",
"url": "https://www.gurufocus.com/news/2899913/in-largest-molecular-residual-disease-mrd-study-in-colon-cancer-guardant-reveal-testing-prior-to-chemotherapy-provides-robust-stratification-for-risk-of-disease-recurrence-and-survival-to-enable-ti",
"image_url": "https://static.gurufocus.com/logos/0C0000BIF0.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.36103,
"sentiment_score": -0.313233,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+319 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em>, <em>I[+202 characters]",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Guardant</em> <em>Health</em>:[+324 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "de5a70d1-c157-4c0a-bc54-7e4bf2b2ffe8",
"title": "Sanofi Stock: Finding Value In The Wake Of Itepekimab's Disappointment (NASDAQ:SNY)",
"description": "Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.",
"keywords": "",
"snippet": "With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks by combining clinical insight with rigorous valuation methods. He specializes...",
"url": "https://seekingalpha.com/article/4791431-sanofi-finding-value-in-the-wake-of-itepekimabs-disappointment",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2035240324/image_2035240324.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T13:15:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "SNY",
"name": "Sanofi",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.172985,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "Sanofi Stock: Finding Value In The Wake Of Itepekimab's Disappointment (<em>NASDAQ:SNY</em>)",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0fe57b14-dcdc-49b5-98ac-616297af79b0",
"title": "Gilead’s Trodelvy with Keytruda cuts breast cancer risk (GILD)",
"description": "Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.",
"keywords": "",
"snippet": "Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut...",
"url": "https://seekingalpha.com/news/4454037-gileads-trodelvy-keytruda-cuts-breast-cancer-risk",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185872237/image_2185872237.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T13:12:40.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 41.3887,
"sentiment_score": -0.9201,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (<em>N[+272 characters]",
"sentiment": -0.9201,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 1688,
"sentiment_avg": 0.28081089837259837
}
]
}
Other details
Entity count
- 32,649